

Shasun Chemicals Q2 FY08 top line grows by 21 % at Rs.131.16 crore**Mumbai, October 16,2007****Quarterly Performance**

Shasun Chemicals and Drugs Ltd., a leading pharma company focused on manufacture of finished dosage, APIs (active pharmaceutical ingredients) and the intermediates to global pharma, posted a 21% per cent growth in revenue at Rs 131.16 crore for the Q2 FY07-08 as compared to Rs 108.38 crore of Q2 FY06-07 on standalone basis.

The standalone net profit for the Q2 FY 07-08 stood at Rs 6.88 crore compared to Rs 7.77 crore in Q2 FY06-07. The growth in CRAMS business has been significant and the total revenue from CRAMS India business for Q2 FY07-08 was Rs. 21.86 crore as compared to Rs. 10.15 crore. EBITDA for the Q2 stood at Rs. 16.25 crore as against Rs.17.03 crore in the previous year's quarter.

Consolidated Half year Performance

For the six months ended September 30, 2007, the company posted a 12% per cent growth in consolidated revenue at Rs 404.69 crore compared to Rs 361.22 in the corresponding period last year. The consolidated result for the half year is a loss of Rs.7.06 crores as against a profit of Rs 23.43 crores in H1 FY07. However on excluding release of negative goodwill, the loss has been reduced to Rs.12.56 crores for H1 FY07-08 from loss of Rs.17.61 crores in H1 FY06-07. The company's UK subsidiary experienced a dip in second quarter due to operational issues at its Annan facility, which resulted in deferral of revenue to the next quarter.

Management Comments

The Management strongly believes in the favorable future value of the business and is fully committed to growing the business by making significant investment for future expansion both in the Indian and UK operations. Further the management would like to take this opportunity to dispel the rumors suggesting sale of any of its businesses.

Event

Shasun will host fifth international conference on catalysis & process chemistry technologies. The conference, which will be held on March 30- April 02 2008, will focus on "asymmetric synthesis – metal coupling reaction and process intensification. The symposium will provide a forum for scientific exchange and the discussion of the latest technologies, developments, and challenges in a setting conducive to networking for international pharmaceutical industry professionals.

About Shasun Chemicals and Drugs Ltd (BSE: 524552, NSE: SHASUNCHEM)

Shasun Chemicals and Drugs Ltd is leading pharma company focused on manufacture of Active Pharmaceutical Ingredients (API's), intermediates and finished dosages to global pharma majors. Founded in 1976, Shasun offers an integrated business model by offering services in research, development and manufacturing (including Contract Research and Manufacturing Services). The company has four bulk manufacturing facilities, two in India and two in UK, which have been inspected successfully several times by various regulatory agencies including US FDA. Its finished dosage facility has been inspected by US FDA, TPD Canada and MHRA, UK.

With its maiden acquisition of business and assets of UK-based Rhodia Pharma through the wholly owned subsidiary Shasun Pharma Solutions Ltd (SPSL), Shasun has now become a multi national company.

For more information, contact:

Rakesh Sharma/ Neha Goenka

Adfactors PR, Mumbai

Phone: 91-22-22813565

Cell: 98214 19263 / 98208 42363

Email: rakesh@adfactorspr.com/

neha.goenka@adfactorspr.com

S. Vimal Kumar

Shasun Chemicals & Drugs Limited

Tel: 91-44-2431 6748

Fax: 91-44-2434 8940

vimal@shasun.com